{"disease":{"id":"influenza-prophylaxis","name":"influenza prophylaxis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06762587","title":"Oseltamivir and Baloxavir Marboxil for Prophylaxis Against Influenza Under a Hospital-based Setting","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":372,"lead_sponsor_name":"Capital Medical University","has_results":false},{"nct_id":"NCT05255822","title":"INNA-051 Influenza Challenge Study","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":123,"lead_sponsor_name":"ENA Respiratory Pty Ltd","has_results":false},{"nct_id":"NCT01863849","title":"Tolerability and Immunogenicity Study of Fluval AB Suspension for Injection","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Fluart Innovative Vaccine Ltd, Hungary","has_results":true}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}